|
US20080300281A1
(en)
*
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
FR2784378B1
(fr)
*
|
1998-10-09 |
2000-12-29 |
Pf Medicament |
Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
|
|
US20080269265A1
(en)
*
|
1998-12-22 |
2008-10-30 |
Scott Miller |
Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
EP1158985B1
(en)
*
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
FR2820743B1
(fr)
*
|
2001-02-09 |
2005-02-25 |
Pf Medicament |
Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine
|
|
US7371763B2
(en)
*
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
|
FR2827172B1
(fr)
*
|
2001-07-13 |
2004-07-02 |
Pf Medicament |
Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
|
|
US8106074B2
(en)
*
|
2001-07-13 |
2012-01-31 |
Pierre Fabre Medicament |
Pyridin-2-yl-methylamine derivatives for treating opiate dependence
|
|
WO2003047579A1
(en)
*
|
2001-12-03 |
2003-06-12 |
Bayer Pharmaceuticals Corporation |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
US20080108672A1
(en)
*
|
2002-01-11 |
2008-05-08 |
Bernd Riedl |
Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
|
|
ATE529406T1
(de)
*
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
KR100435105B1
(ko)
*
|
2002-04-17 |
2004-06-09 |
금호석유화학 주식회사 |
카르복시이미데이트 리간드에 기초한 원자이동 라디칼중합을 이용한 새로운 메틸메타아크릴레이트의 중합방법
|
|
FR2840900B1
(fr)
*
|
2002-06-18 |
2005-02-25 |
Pf Medicament |
Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
FR2852244B1
(fr)
*
|
2003-03-13 |
2007-09-07 |
Pf Medicament |
Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
|
|
EP1636585B2
(en)
*
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
EP1663978B1
(en)
*
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
FR2891274B1
(fr)
*
|
2005-09-27 |
2007-11-23 |
Pierre Fabre Medicament Sa |
Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires.
|
|
EP2058306A1
(en)
*
|
2007-11-08 |
2009-05-13 |
Schwarz Pharma Ag |
Heteroaryl-substituted 2-pyridinyl-methylamine derivatives
|
|
EP2699569B1
(en)
*
|
2011-04-22 |
2017-08-30 |
Jasco Pharmaceuticals, LLC |
Aminopyrimidine kinase inhibitors
|
|
RU2702101C2
(ru)
|
2014-07-09 |
2019-10-04 |
Пьер Фабр Медикамент |
Способ лечения двигательных расстройств бефирадолом
|
|
EP3260452A1
(en)
*
|
2016-06-24 |
2017-12-27 |
Neurolixis |
Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
|
|
US10626105B2
(en)
|
2016-09-22 |
2020-04-21 |
Auspex Pharmaceuticals, Inc. |
Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
|
|
EP3664787B1
(en)
|
2017-07-20 |
2022-07-20 |
Neurolixis |
Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
|
|
AU2024238367A1
(en)
|
2023-03-19 |
2025-10-09 |
Neurolixis, Inc. |
Method for treating l-dopa-induced dyskinesia using befiradol
|